Research indicates that in NSCLC cells resistant to EGFR-TKIs, diminished expression of SFRP5 triggers the activation of the Wnt pathway, facilitating tumor advancement and drug resistance via EMT and Akt2 signaling pathways mediated by TWIST [41]. Here, SFRP5 is linked to non-small cell lung carcinoma.